PD-1 antibodies in head-and-neck cancer-Reference-Cited by-同舟云学术

PD-1 antibodies in head-and-neck cancer

Published:2019-01 Issue:10167 Volume:393 Page:108-109
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Wollenberg Barbara

Publisher

Elsevier BV

Subject

General Medicine

Reference8 articles.

1. Nivolumab for recurrent squamous-cell carcinoma of the head and neck;Ferris;N Engl J Med,2016

2. Inhibitors of the PD-1/PD-L1 axis for the treatment of head and neck cancer: current status and future perspectives;Ran;Drug Des Devel Ther,2017

3. Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma;Saâda-Bouzid;Ann Oncol,2017

4. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study;Cohen;Lancet,2018

5. Cancer immunology. The “cancer immunogram”;Blank;Science,2016

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Integrated Molecular and Histological Insights for Targeted Therapies in Mesenchymal Sinonasal Tract Tumors;Current Oncology Reports;2024-02-20

2. The Role of Different Immunocompetent Cell Populations in the Pathogenesis of Head and Neck Cancer—Regulatory Mechanisms of Pro- and Anti-Cancer Activity and Their Impact on Immunotherapy;Cancers;2023-03-07

3. A Physiologically Responsive Nanocomposite Hydrogel for Treatment of Head and Neck Squamous Cell Carcinoma via Proteolysis‐Targeting Chimeras Enhanced Immunotherapy;Advanced Materials;2023-02-10

4. Comprehensive Characterization of Immune Landscape Based on Epithelial-Mesenchymal Transition Signature in OSCC: Implication for Prognosis and Immunotherapy;Frontiers in Oncology;2021-07-01

5. Comprehensive co‑expression analysis reveals TMC8 as a prognostic immune‑associated gene in head and neck squamous cancer;Oncology Letters;2021-04-27